Corporate Social Responsibility Report

The report highlights 2016 progress in oncology and ophthalmology R&D, including the Aplidin marketing application and clinical-trial developments. It reports 713 employees at year-end and states that there were no environmental incidents or sanctions across Group companies. Environmental stewardship includes ISO 14001 certification for PharmaMar and Xylazel, carbon-footprint calculation, selective marine sampling and a signed Pact for Biodiversity.